# Jessica C. Hassel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jessica-c-hassel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,788 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 68 |
| i10-index | 244 |
| Last Known Institution | Heidelberg University |
| OpenAlex ID | https://openalex.org/A5067776208 |
| ORCID iD | https://orcid.org/0000-0001-7575-6230 |
| Works | 627 |

## Researcher papers

- [Genomic correlates of response to CTLA-4 blockade in metastatic melanoma](https://scholariq.org/papers/genomic-correlates-of-response-to-ctla-4-blockade-in-metastatic-melanoma/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab](https://scholariq.org/papers/anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Heidelberg University](https://scholariq.org/institutions/heidelberg-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.